Showing results (41-50 of 132) with videos related to
Sort By:
Pageof 14
Current Neuropharmacology|July 11, 2008
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegenerationJohn C Ashton, Michelle GlassJournal of Pharmacological and Toxicological Methods|December 6, 2014
Increasing the flexibility of the LANCE cAMP detection kitMorag Rose Hunter, Michelle GlassDrug Testing and Analysis|March 7, 2019
The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogsSamuel D Banister, Richard C Kevin, Lewis Martin, et al.Journal of Chemical Information and Modeling|August 4, 2023
A Novel "Activation Switch" Motif Common to All Aminergic ReceptorsKuo Hao Lee, Jamie J Manning, Jonathan Javitch, et al.Advances in Pharmacology (San Diego, Calif.)|August 23, 2017
Functional Selectivity at Cannabinoid ReceptorsRichard Priestley, Michelle Glass, David KendallPharmacology, Biochemistry, and Behavior|April 6, 2020
In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018Thomas F Gamage, Daniel G Barrus, Richard C Kevin, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 20, 2003
Cannabis, cannabinoids and reproductionBoram Park, John M McPartland, Michelle GlassCannabis and Cannabinoid Research|September 2, 2017
Cannabinoid CB1 and CB2 Receptor Signaling and BiasMikkel Søes Ibsen, Mark Connor, Michelle GlassFrontiers in Cell and Developmental Biology|September 1, 2023
Methods for automating the analysis of live-cell single-molecule FRET dataJozsef Meszaros, Peter Geggier, Jamie J Manning, et al.British Journal of Pharmacology|July 2, 2010
The endocannabinoid system as a target for the treatment of neurodegenerative diseaseEmma L Scotter, Mary E Abood, Michelle GlassPageof 14